AbbVie (NYSE: ABBV) reported Q1 EPS of $2.95, $0.12 better than the analyst estimate of $2.83. Revenue for the quarter came in at $12.94 billion versus the consensus estimate of $12.76 billion.

GUIDANCE:

AbbVie sees FY2021 EPS of $12.37-$12.57, versus the consensus of $12.45.

• AbbVie is raising its GAAP diluted EPS guidance for the full-year 2021 from $6.69 to $6.89 to $7.27 to $7.47. AbbVie is raising its adjusted diluted EPS for the full-year 2021 from $12.32 to $12.52 to $12.37 to $12.57. The company's 2021 adjusted diluted EPS guidance excludes $5.10 per share of intangible asset amortization expense, non-cash charges for contingent consideration adjustments and other specified items.

For earnings history and earnings-related data on AbbVie (ABBV) click here.